Supplemental Figure S8.

Representative images of Ki-67 and urothelial marker staining in keratinocyte growth factor (KGF)–pretreated bladders from 28 days after cyclophosphamide injection. A and F: Immunofluorescence (IF) for KRT20 (red) shows regions of incomplete staining along the lumenal surface of PBS-pretreated mice (arrowhead), whereas KGF-pretreated mice have strong, continuous signal (F) 28 days after injury. B–D: Triple-label IF for Ki-67 (red), uroplakin 3a (UPK3; white), and KRT5 (green) in a section adjacent to A shows that PBS-pretreated mice still have proliferating cells along the basal layer that colabel for KRT5 and not UPK3 (arrowheads), 28 days after injury. E: Co-IF for Ki-67 (red) and KRT14 (white) in a section adjacent to D shows that PBS-pretreated mice continue to have many KRT14⁺ cells along the basal layer, many of which are proliferating (concave arrowheads) 28 days after injury. G–I: Triple-label IF for Ki-67 (red), UPK3 (white), and KRT5 (green) in a section adjacent to F shows that KGF-pretreated mice have no proliferating urothelial cells, including in UPK3⁺ and KRT5⁺ cells. J: Co-IF for Ki-67 (red) and KRT14 (white) in a section adjacent to I confirms that KGF-pretreated urothelial cells are not proliferating, although small patches of persistent KRT14⁺ cells are apparent along the basal layer (arrows) 28 days after injury. A, B, F, and G: Blue indicates DAPI. Scale bar = 50 μm (A–J). L, lumen.